The global schizophrenia drugs market size was valued at USD 7.88 billion in 2024 and is projected to reach from USD 8.28 ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Brexpiprazole is used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults, ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Schizophrenia usually starts in your late teens or young adulthood and is a lifelong condition. If you get catatonia, your episodes may come and go. But the right treatment will usually help ease ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug ... trospium chloride – as a treatment for adults with schizophrenia by 26th September.

Assisted outpatient treatment (also known as outpatient ... and the suicide rate for adults with schizophrenia is about 4.5 times higher than for the general population. Once your loved one ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...